Details for Patent: 9,951,043
✉ Email this page to a colleague
Which drugs does patent 9,951,043 protect, and when does it expire?
Patent 9,951,043 protects SUNLENCA and is included in two NDAs.
This patent has sixty-six patent family members in thirty-six countries.
Summary for Patent: 9,951,043
| Title: | Therapeutic compounds |
| Abstract: | Compounds of formula (I) or salts thereof are disclosed. Also disclosed are pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I and therapeutic methods for treating a Retroviridae viral infection including an infection caused by the HIV virus. |
| Inventor(s): | Brizgys Gediminas, Canales Eda, Chou Chien-hung, Graupe Michael, Halcomb Randall L., Hu Yunfeng Eric, Lazerwith Scott E., Link John O., Liu Qi, Lu Yafan, Saito Roland D., Schroeder Scott D., Somoza John R., Tse Winston C., Zhang Jennifer R. |
| Assignee: | Gilead Sciences, Inc. |
| Application Number: | US14771779 |
|
Patent Claim Types: see list of patent claims |
Drugs Protected by US Patent 9,951,043
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gilead Sciences Inc | SUNLENCA | lenacapavir sodium | SOLUTION;SUBCUTANEOUS | 215973-001 | Dec 22, 2022 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | IN COMBINATION WITH OTHER ANTIRETROVIRAL(S), FOR THE TREATMENT OF HIV-1 INFECTION IN HEAVILY-TREATMENT EXPERIENCED ADULTS WITH MULTIDRUG RESISTANT HIV-1 INFECTION | ⤷ Sign Up | ||
| Gilead Sciences Inc | SUNLENCA | lenacapavir sodium | TABLET;ORAL | 215974-001 | Dec 22, 2022 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | IN COMBINATION WITH OTHER ANTIRETROVIRAL(S), FOR THE TREATMENT OF HIV-1 INFECTION IN HEAVILY-TREATMENT EXPERIENCED ADULTS WITH MULTIDRUG RESISTANT HIV-1 INFECTION | ⤷ Sign Up | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,951,043
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 094990 | ⤷ Sign Up | |||
| Argentina | 118856 | ⤷ Sign Up | |||
| Australia | 2014223973 | ⤷ Sign Up | |||
| Australia | 2016262671 | ⤷ Sign Up | |||
| Australia | 2018247348 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
